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IRCCS, Rome, ItalyDonnai-Barrow syndrome (DBS) is an autosomal-recessive
disorder characterized by multiple pathologies including
malformation of forebrain and eyes, as well as resorption
defects of the kidney proximal tubule. The underlying
cause of DBS are mutations in LRP2, encoding the
multifunctional endocytic receptor megalin. Here, we
identified a unique missense mutation R3192Q of LRP2 in
an affected family that may provide novel insights into the
molecular causes of receptor dysfunction in the kidney
proximal tubule and other tissues affected in DBS. Using
patient-derived induced pluripotent stem cell lines we
generated neuroepithelial and kidney cell types as models
of the disease. Using these cell models, we documented the
inability of megalin R3192Q to properly discharge ligand
and ligand-induced receptor decay in lysosomes. Thus,
mutant receptors are aberrantly targeted to lysosomes for
catabolism, essentially depleting megalin in the presence
of ligand in this affected family.
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2020D onnai-Barrow/Facio-oculo-acoustico-renal syndrome(herein referred to as DBS) is an autosomal recessivedisorder caused by inheritable mutations in LRP2
(low-density lipoprotein receptor–related protein 2).1,2 This
gene encodes the endocytic receptor megalin that acts as a
high-capacity clearance pathway for numerous ligands in
absorptive epithelia, most notably in the developing forebrain
and retina3-5 and in the proximal tubules of the adult kid-
ney.6,7 Some variability exists in the extent of malformation
of forebrain and facial structures in patients with DBS, defects
attributed to the loss of receptor expression in neuroepithelial
cells of the developing central nervous system.2,8-10 By
contrast, patients with DBS invariably suffer from renal
resorption defects (renal Fanconi syndrome) characterized
by urinary loss of megalin ligands, including vitamins D, A,
and B12 bound to their plasma carrier proteins.1,11,12 This
observation underscores the central role played by megalin
in proximal tubular retrieval processes in humans.
Despite its importance for renal (patho)physiology, little is
known about the functional organization of the giant 600 kDa
receptor megalin and the molecular mechanisms that define
its ability to act as a clearance pathway in the kidney and
other tissues of the human body. Naturally occurring muta-
tions in DBS may shed light on essential protein domains
altered in the mutant receptors. However, most known LRP2
mutations encode truncated soluble fragments offering little
conceptual advance on the functional organization of the
receptor polypeptide.1 Here, we report the identification of a
novel missense mutation LRP2R3192Q in 2 siblings with DBS.
Using human disease modeling in neuroepithelial and renal
cell types generated from induced pluripotent stem cells
(iPSCs) of both individuals, we document that mutation
LRP2R3192Q disrupts the ability of megalin to properly
discharge internalized ligand. As a consequence, mutant re-
ceptors are aberrantly targeted to lysosomes for catabolism,
essentially depleting DBS cells for megalin in the presence of
ligand.
RESULTS
iPSC-derived cell lines for disease modeling of DBS
We identified 2 siblings who presented with clinical symp-
toms of renal Fanconi syndrome, including hypercalciuria
and abnormal urinary excretion of low-molecular-weight159
Figure 1 | Mutation c:G9575A in Donnai-Barrow syndrome disrupts renal megalinR3192Q expression. (a) Structural organization of the
megalin polypeptide composed of complement-type repeats (CR), epidermal growth factor (EGF)–type repeats, and b-propellers. Mutation
R3192Q (encoded by c:G9575A) in an EGF-type repeat is indicated by the red asterisk. (b) Immunohistological detection of megalin
(arrowheads) in proximal tubule cells of kidney biopsies from a control subject but not from patient R3192Q_2. (c) Western blot analysis of spot
urine documenting urinary loss of the megalin ligands vitamin D–binding protein (DBP), retinol-binding protein (RBP), a1-microglobulin, and
b2-microglobulin in patients R3192Q_1 and R3192Q_2, but not in 3 control subjects. (d) Sequence analysis showing a homozygous mutation
c:G9575A (red box) in LRP2 in induced pluripotent stem cell lines derived from patients R3192Q_1 and R3192Q_2 as compared with a control
cell line. Sequences were aligned to the LRP2 reference sequence given above (NCBI reference sequence: NM_004525.2). To optimize viewing
of this image, please see the online version of this article at www.kidney-international.org.
c l i n i ca l i nves t iga t i on J Flemming et al.: Molecular cause of megalin deficiencyproteins at the age of 7 and 9, respectively (see the Patient
information section for more clinical details). Exome
sequencing identified homozygosity for mutation c:G9575A
in LRP2 in both individuals, resulting in amino acid alteration
R3192Q in an epidermal growth factor–type repeat in the
extracellular megalin domain (Figure 1a). Megalin deficiency
as the underlying cause of renal Fanconi syndrome was
confirmed by the absence of receptor expression in renal bi-
opsies (Figure 1b) and by aberrant urinary excretion of
known receptor ligands (Figure 1c) in the affected individuals
R3192Q_1 and R3192Q_2.
To elucidate the mechanism impairing megalinR3192Q
expression, we generated iPSC lines by reprogramming periph-
eral blood mononuclear cells from both patients. Homozygosity
for c:G9575A in the iPSC lines was confirmed by DNA
sequencing (Figure 1d). Karyotyping of peripheral blood
mononuclear cells, and iPSC lines derived thereof, identified
copy neutral loss of heterozygosity at 2q23.3-q31.1 as the reason
for homozygosity for c:G9575A (Supplementary Figure S1A
and B). Minor alterations in other chromosomal regions
common to peripheral blood mononuclear cells and iPSC
lines were considered irrelevant to explain the loss of renal
megalin expression in the affected individuals (Supplementary
Figure S1C and D).
iPSC lines from patients R3192Q_1 and R3192Q_2
showed robust expression of pluripotency markers
(Supplementary Figure S2A and B) and the expected potential
to differentiate into all 3 germ layers (Supplementary
Figure S2C and D). To derive a cell model for studying the
molecular mechanism underlying loss of megalinR3192Q
expression, we initially applied a protocol whereby iPSCs were
differentiated into neural precursor cells (NPCs), the pro-
genitor cell population for various cell types of the developing
central nervous system (Supplementary Figure S3A).13 We160chose this differentiation protocol for our initial studies
because of its robustness and reproducibility, and because it
recapitulates expression of megalin in this cell type in vivo.4,14
Both patient cell lines faithfully recapitulated neuro-
ectodermal differentiation as exemplified by induction of
neuroectodermal markers PAX6 and SOX1, and by a
concomitant loss of pluripotency marker OCT4
(Supplementary Figure S3B–E).
When expression of megalin during neuroectodermal
differentiation was tested by immunocytochemistry, robust
induction of receptor levels was seen in R3192Q_1 and
control cell lines at day 5 of differentiation (Figure 2a).
However, megalin levels decreased significantly by day 9 in
patient as compared with control cells (Figure 2a). Loss of
megalinR3192Q at later stages of differentiation was not due
to a decrease in gene transcription, as LRP2 transcript levels
were similar to control cells at days 5 and 9 of differenti-
ation (Figure 2b). The reduced level of megalin protein, but
not transcript at day 9 of differentiation, was substantiated
by Western blot (Figure 2c and d) and quantitative real-
time polymerase chain reaction analysis (Figure 2e),
respectively. Post-transcriptional loss of megalin expression
was reproduced in an iPSC line from patient R3192Q_2
using immunocytochemistry and quantitative real-time
polymerase chain reaction (Supplementary Figure S4A, B,
and E), as well as Western blotting (Supplementary
Figure S4C and D).
Mutation R3192Q does not abolish the endocytic activity of
megalin
To interrogate the impact of mutation R3192Q on the activity
of megalin, we established an endocytosis assay in NPCs using
the amino terminal fragment of sonic hedgehog (SHH-N)
fused to glutathione S-transferase, a megalin ligand in severalKidney International (2020) 98, 159–167
Figure 2 | Cellular expression of megalinR3192Q is impacted by a post-transcriptional mechanism. (a) Immunodetection of megalin (red)
in induced pluripotent stem cell (iPSC) lines at the indicated time points of neuroectodermal differentiation. Cells were counterstained with
40,6-diamidino-2-phenylindole (DAPI) (blue). Megalin expression was induced from day 5 onward in both genotypes. At day 9, receptor levels
decreased in patient-derived cells as compared with control cells. Bar ¼ 10 mm. (b) Transcript levels of LRP2 during differentiation into
neuroectoderm cells in the control subject and patient R3192Q_1. Data are depicted as Dct normalized to day 0 of the control cells (DDct) 
SD; n ¼ 4 experiments with 2–3 biological replicates/experiment. Statistical analyses were performed by 2-way analysis of variance with the
Bonferroni post-test. *P < 0.05; ***P < 0.001. (c) Western blot analysis of megalin in R3192Q_1 and control iPSC lines at the indicated time
points of neuroectodermal differentiation. The detection of a-tubulin served as loading control. (d) Megalin levels were quantified by
densitometric scanning of replicate Western blots (exemplified in panel c) in control and R3192Q_1 neural precursor cells (NPCs) at days 5 and
9 of differentiation (n ¼ 2–3 independent experiments, 2–4 biological replicates/experiment). Megalin levels in R3192Q_1 cells were
comparable with control cells at day 5, but significantly decreased at day 9 of differentiation. Values are given as relative levels of expression
compared with controls (set to 100%  SD). Statistical significance was determined by Student’s t test (day 9) or 1-paired t test (day 5). ****P <
0.0001. (e) Quantitative real-time polymerase chain reaction analysis of LRP2 transcript levels in a control and R3192Q_1 NPCs at days 5 and 9
of differentiation. (n ¼ 3 independent experiments, 2–4 biological replicates/experiment). Levels are depicted as ct values normalized to
transcript levels of GAPDH (Dct  SD) used as an internal control. Transcript levels for LRP2 are unchanged at days 5 and 9 comparing
genotypes (Student’s t test). To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
J Flemming et al.: Molecular cause of megalin deficiency c l i n i ca l i nves t iga t iontissues.4,15 To first establish the validity of this assay for
scoring megalin activity, we used a CRISPR/Cas9 strategy to
disrupt the megalin coding sequence in the control cell line
used in this study and to generate a cell clone genetically
deficient for this receptor (LRP2/; Supplementary
Figure S5A). Deletion of the ATG codon in the LRP2 gene
locus completely ablated megalin expression in this cell clone
as shown by Western blot analysis (Supplementary
Figure S5B). The absence of megalin severely reduced the
uptake of GST-SHH-N in LRP2/ NPCs as compared with
parental cells (LRP2þ/þ) as documented by immunocyto-
chemistry (Supplementary Figure S5C), identifying megalin
as the major endocytic route for SHH-N in NPCs. To more
accurately assess the quantitative contribution of megalin to
SHH-N uptake in these cells, we treated LRP2/ and control
NPCs with GST-SHH-N and determined the amount ofKidney International (2020) 98, 159–167cell-associated ligand thereafter using Western blotting
(Supplementary Figure S5B). Megalin deficiency reduced the
amount of GST-SHH-N in the LRP2/ cell fraction by 50%
as compared with control cells, underscoring the significance
of megalin as the SHH receptor in NPCs (Supplementary
Figure S5D). The residual amount of GST-SHH-N associ-
ated with LRP2/ NPCs likely reflected adherence of the
ligand to the cellular surface, although the existence of other
uptake mechanisms, such as through the receptor Patched1,
cannot be excluded.
Next, we used the GST-SHH-N uptake assay to assess the
receptor activity in the patient cell line R3192Q_1. Ligand
uptake was reduced in these cells as compared with control
NPCs as documented by immunocytochemistry (Figure 3a)
and quantitative Western blotting (Figure 3b and c). Still, the
megalin-mediated uptake of GST-SHH-N in the cell line161
Figure 3 | Mutation c:G9575A does not impact the endocytic
activity of megalinR3192Q. (a) Neural precursor cells (NPCs) from a
control or from patient R3192Q_1 were treated for 2 hours in
medium containing 10 mg/ml recombinant GST-SHH-N.
Subsequently, cells were immunostained for GST-SHH-N (red) using
anti-GST antisera and counterstained with 40,6-diamidino-2-
phenylindole (DAPI) (blue). Bar ¼ 25 mm. (b) NPCs from a control or
from patient R3192Q_1 at day 9 of differentiation were treated
overnight in medium with (þ) or without () 10 mg/ml
recombinant GST-SHH-N. Thereafter, levels of megalin and GST-
SHH-N in cell extracts were determined by Western blotting.
Detection of a-tubulin served as loading control. (c) Quantification
of GST-SHH-N uptake in control and R3192Q_1 cells by
densitometric scanning of replicate Western blots (exemplified in
panel b). Levels are given relative to control cells (set to 100% 
SD). The amount of internalized GST-SHH-N is significantly lower in
cells from patients R3192Q_1 as compared with control cells (n ¼ 3
independent experiments, 2–4 biological replicates/experiment;
Student’s t test). *P < 0.05. To optimize viewing of this image,
please see the online version of this article at www.kidney-
international.org.
c l i n i ca l i nves t iga t i on J Flemming et al.: Molecular cause of megalin deficiencyR3192Q_1 was apparent and substantially higher than in
receptor null cells (75% of control in Figure 3c vs. 50% of
control in Supplementary Figure S5D). These findings indi-
cated that impaired expression of megalinR3192Q reduced but
did not abolish the ability of NPCs to internalize receptor
ligands.162SHH induces loss of megalinR3192Q expression in
neuroepithelial and renal cell types
Our data revealed the surprising finding that mutation
R3192Q did not ablate expression or endocytic activity of
megalin but impacted receptor levels by a post-transcriptional
mechanism. As our differentiation protocol entailed the
addition of SHH at day 5 of differentiation (Supplementary
Figure S3A), we reasoned that this ligand may trigger the
decline in megalinR3192Q levels seen at day 9. To test this
hypothesis, we used NPCs at day 5 of differentiation and
incubated them with or without GST-SHH-N. The addition
of ligand resulted in significantly lower megalin levels in the
patient cell line R3192Q_1 (Figure 4a and b) as compared
with the untreated cells. Similarly, levels of mutant megalin
were also decreased on ligand exposure in the patient cell line
R3192Q_2, although an increase in wild-type receptor
contributed to the difference in megalin levels seen between
patient 2 and control cells (Supplementary Figure S6A and B).
Decreased levels of megalinR3192Q in the presence of GST-
SHH-N were due to a reduced half-life of the mutant re-
ceptor as shown by determining protein stability in NPCs
treated with cycloheximide, an inhibitor of protein translation
(Figure 4c and d).
To substantiate that ligand-induced decay of megalinR3192Q
was also seen in renal cell types and potentially responsible for
renal Fanconi syndrome in affected individuals, we applied an
established protocol to differentiate iPSCs into renal proximal
tubule epithelial-like cells (RPTECs)16 (Supplementary
Figure S7A). Differentiation into the proper renal cell type
was documented by transient expression of mesodermal
marker T/Brachyury and early proximal renal vesicle marker
JAG1, as well as by stable induction of proximal tubule
markers AQP1 and LRP2 (Supplementary Figure S7B).
Coexpression of AQP1 and megalin in the differentiated cells
was substantiated by immunocytochemistry (Supplementary
Figure S7C). As shown for NPCs above, the addition of
GST-SHH-N resulted in lower megalin levels in R3192Q_1 as
compared with control cells (Figure 5a and b). To query
whether other receptor ligands may also impact expression of
megalinR3192Q in RPTECs, we tested the effect of lysozyme, a
protein cleared from the glomerular filtrate by megalin.17
Contrary to SHH-N, the addition of lysozyme to the cell
medium did not impact levels of megalinR3192Q
(Supplementary Figure S8).
Aberrant lysosomal targeting of receptor/SHH complexes
induces catabolism of megalinR3192Q
To explore the reasons for the reduced stability of mega-
linR3192Q in the presence of GST-SHH-N, we studied the
subcellular localization of the receptor and ligand. When
the subcellular localizations of megalin and internalized
GST-SHH-N were tested by immunocytochemistry in
NPCs, an increased colocalization of megalinR3192Q with
this ligand was observed in both patients’ cell lines as
compared with the wild-type receptor (Figure 6a and b;
Supplementary Figure S9A and B). As shown by co-Kidney International (2020) 98, 159–167
Figure 4 | The addition of SHH-N decreases stability of megalinR3192Q in neural precursor cells (NPCs). (a) NPCs at day 5 of
differentiation were treated with 10 mg/ml GST-SHH-N or blank medium overnight, and levels of megalin were determined in cell lysates by
Western blotting thereafter. Detection of a-tubulin served as a loading control. (b) Quantification of megalin levels in control and R3192Q_1
NPC lines by densitometric scanning of replicate Western blots (exemplified in panel a). Levels are given as relative to the untreated condition
(set to 100%  SD). In the presence of GST-SHH-N, levels of megalinR3192Q were significantly lower compared with that of the wild-type
receptor (n ¼ 4 independent experiments, 2–3 biological replicates/experiment). This difference was not seen in the control medium (blank)
lacking the receptor ligand. Statistical significance was determined using Student’s t test. *P < 0.05; **P < 0.01. (c) Replicate layers of control
and R3192Q_1 NPCs at day 5 of differentiation were treated with 10 mg/ml GST-SHH-N and 7.5 mg/ml cycloheximide. Cells were harvested at
the indicated time points, and expression levels of megalin were determined by Western blotting. Detection of a-tubulin served as a loading
control. (d) Megalin levels were quantified by densitometric scanning of replicate Western blots (exemplified in panel c) in control and
R3192Q_1 NPCs after treatment with GST-SHH-N and cycloheximide (mean of 3 independent experiments). Receptor levels are given as a
percentage of levels at time point 0 of treatment for each cell line. In the presence of a ligand, a significantly faster decay was observed for
megalinR3192Q as compared with the wild-type receptor (P < 0.0001 for genotype and time, unmatched 2-way analysis of variance).
J Flemming et al.: Molecular cause of megalin deficiency c l i n i ca l i nves t iga t ionimmunostaining with lysosomal marker LAMP1, the addi-
tion of ligand provided a protective effect to wild-type
megalin reducing its localization to LAMP1þ lysosomes.
This protective effect was not seen with megalinR3192Q,
resulting in enhanced lysosomal trapping in the presence of
ligand as compared with the wild-type receptor (Figure 6c
and d; Supplementary Figure S9C and D). No difference in
lysosomal targeting of megalin was seen between mutant
and control cells when treated with GST only (Figure 6c
and d; Supplementary Figure S9C and D). Triple immu-
nostaining substantiated enhanced colocalization of mega-
linR3192Q and GST-SHH-N in LAMP1þ lysosomes
(Figure 6e).
To further corroborate ligand-induced lysosomal catabo-
lism of megalinR3192Q as a molecular cause of DBS, we treated
control and mutant NPCs with GST-SHH-N in the presence
or absence of lysosomal inhibitors. Lysosomal blockade did
not alter the levels of wild-type megalin, but it significantly
increased levels of the mutant receptor (Figure 7). These
findings further substantiated that lysosomal degradation
significantly contributes to the reduced stability of mega-
linR3192Q in DBS.Kidney International (2020) 98, 159–167DISCUSSION
Megalin is the main endocytic receptor in the proximal
convoluted tubules for bulk clearance of plasma proteins
from the glomerular filtrate.6,7,17,18 Megalin-mediated clear-
ance of ligands has also been shown in other absorptive
epithelia, including the neural tube,4 the epididymis,19 and
the retinal pigment epithelium.5 So far, the inability to
recombinantly express full-length megalin has hampered at-
tempts to dissect functional domains in the receptor poly-
peptide. Now, the availability of naturally occurring LRP2
mutations in patients with DBS and the ability to recapitulate
mutant phenotypes in iPSC-derived cell models significantly
advance our abilities to study megalin in human health and
disease. This assumption is substantiated by our studies of
individuals homozygous for a novel LRP2 mutation
c:G9575A. Based on the absence of megalin in renal biopsies
(Figure 1b), the inability to properly fold and express mega-
linR3192Q may have been anticipated as a consequence of this
mutation. However, studies in iPSC-derived cell lines docu-
ment proper expression of the mutant receptor in the absence
of ligands in neuroepithelial (Figure 2a and Supplementary
Figure S4A) and proximal tubule (Supplementary163
Figure 5 | Ligand-induced decay of megalinR3192Q in induced
pluripotent stem cell (iPSC)–derived renal proximal tubule
epithelial-like cells (RPTECs). (a) Control and patient iPSC-derived
RPTECs at day 8 of differentiation were treated with 10 mg/ml GST-
SHH-N or blank (10 mg/ml GST) medium overnight. Subsequently,
megalin levels in cell lysates were determined by Western blotting.
Detection of a-tubulin served as a loading control. (b) Megalin
levels in a control and R3192Q_1 RPTECs were quantified by
densitometric scanning of replicate Western blots (exemplified in
panel a). Levels are given as relative to the untreated condition (set
at 100%  SD). In the presence of GST-SHH-N, levels of
megalinR3192Q were significantly lower as compared with the wild-
type receptor (n ¼ 3 independent experiments, 2–3 biological
replicates/experiment). Statistical significance was determined
using Student’s t test. *P < 0.05.
c l i n i ca l i nves t iga t i on J Flemming et al.: Molecular cause of megalin deficiencyFigure S7C) cell types. Also, the ability to perform endocy-
tosis does not seem to be overtly impacted as judged from
the ability of the mutant receptor to clear the ligands SHH-
N (Figure 3) and lysozyme (Supplementary Figure S8).
Rather, extended retention of receptor/ligand complexes
(Figure 6a and b; Supplementary Figure S9AB and B) and
enhanced accumulation of the receptor to lysosomal com-
partments in the presence of ligands (Figure 6c–e;
Supplementary Figure S9C and D) argue for the induced
decay of megalinR3192Q because of an inability to properly
discharge some ligands in the endocytic pathway. Blockade
of lysosomal activity significantly increases levels of mega-
linR3192Q but not of the wild-type receptor (Figure 7). This
finding supports targeting to lysosomes as a factor that
specifically contributes to the impaired stability of the
mutant receptor in neuroepithelial and renal cells types.
Remarkably, a similar mechanism has been identified as a
cause of low-density lipoprotein receptor deficiency in fa-
milial hypercholesterolemia (class 5 mutations).20 Our hy-
pothesis is backed by the localization of R3192Q in an
epidermal growth factor–type repeat, a domain required for
endosomal discharge of ligands by the low-density lipo-
protein receptor.21164Much of our cell biological studies have focused on the
interaction of megalin with its ligand SHH-N in NPCs, an
interaction considered crucial to the role of this receptor in
the development of forebrain and eyes.3,4 Individuals ho-
mozygous for LRP2R3192Q do not present with obvious
craniofacial malformations, recapitulating earlier observa-
tions that missense mutations in LRP2 feature mild forms or
even the absence of forebrain anomalies.8,9 However, both
individuals present with severe myopia (þ7 and þ9 dioptres,
respectively), indicating massive overgrowth of the eyes as a
consequence of potentially impaired uptake of SHH-N3 and
other megalin ligands5 in the retinal pigment epithelium.
Although aberrant targeting of megalinR3192Q to lysosomes
has only been shown directly in NPCs, the ability of SHH-N
to induce the decay of the mutant receptor in iPSC-derived
RPTECs strongly argues that a similar disease mechanism is
operable in the kidney and responsible for renal Fanconi
syndrome in this family with DBS.
As megalin acts as a high-capacity clearance receptor for
numerous ligands in the renal proximal tubule, the question
remains whether only SHH-N or also other receptor ligands
destine megalinR3192Q to lysosomal catabolism. Conceivably,
the induced decay of the mutant receptor may be caused by
ligands, which binding sites are altered by c:G9575A, but not
by others not impacted by this mutation. In our hands,
lysozyme did not decrease the stability of the mutant receptor
in RPTECs (Supplementary Figure S8), documenting that the
proposed disease mechanism is not applicable to every ligand.
Unfortunately, little is known about the exact binding sites for
SHH, lysozyme, or most other receptor ligands that may
guide our choice of alternative ligands to be tested. Still,
irrespective of the number of ligands that may cause the
lysosomal decay of megalinR3192Q, our findings highlight an
important new concept in receptor cell biology, relevant for
pathophysiology of the kidney and other tissues that require
the endocytic activity of megalin.METHODS
Patient information
The patients are son and daughter of apparently unrelated parents
originating from the same small town in Italy. They were diagnosed
with proteinuria when aged 7 and 9 years, respectively. The brother
presented first, after discovering proteinuria in a spot urine analysis
(30 mg/dl) performed during a varicella zoster infection. Further
investigations revealed mild kidney insufficiency (estimated glomer-
ular filtration rate: 86 ml/min per 1.73 m2), increased urinary protein/
creatinine ratio (1.35 mg/mg [n.v. < 0.2 mg/mg]), hypercalciuria
(urinary calcium/creatinine ratio: 0.31 mg/mg [n.v. < 0.2 mg/mg]),
and abnormal urinary excretion of low-molecular-weight proteins
(urinary beta 2 microglobulin/creatinine ratio: 0.48 mg/mg [n.v. ab-
sent]). Other tests showed normal serum bicarbonate levels, normal
renal phosphate handling (serum phosphate: 5.1 mg/dl [n.v. > 3.5
mg/dl]; TmP/GFR: 4.2 mg/dl [n.v. > 2.9 mg/dl]), and normal excre-
tion of amino acids, glucose, uric acid, sodium, and magnesium. The
urine sediment was normal. Renal ultrasound showed normal sized
kidneys (approximately 10th percentile), with very mild hyper-
echogenicity. The physical examination was unremarkable, except forKidney International (2020) 98, 159–167
Figure 6 | Binding of GST-SHH-N directs megalinR3192Q to lysosomes. (a) Immunofluorescence detection of megalin (red) and GST-SHH-N
(green) in control and patient neural precursor cells (NPCs) at day 7 of differentiation treated with 10 mg/ml GST-SHH-N for 2 hours. Cells were
counterstained with 40 ,6-diamidino-2-phenylindole (DAPI) (blue). Bar ¼ 8 mm. (b) Extent of colocalization of megalin with GST-SHH-N as
determined by Mander’s colocalization coefficient is increased for megalinR3192Q as compared with wild-type megalin, suggesting the
prolonged interaction of the mutant receptor with its ligand. One representative experiment is shown with data given as mean  SD. This
experiment was repeated 4 times with 25–40 cells/experiment analyzed. All 4 experiments showed statistical significance (Student’s t test).
***P < 0.0001. (c) Immunofluorescence detection of megalin (red) and lysosomal marker LAMP1 (green) in control and patient NPCs at day 7 of
differentiation treated with 10 mg/ml GST or GST-SHH-N for 2 hours. Cells were counterstained with DAPI. Bar ¼ 8 mm. (d) Mander’s
colocalization coefficient documents increased colocalization of megalinR3192Q with LAMP1 in NPCs treated with GST-SHH-N (but not GST) as
compared with wild-type megalin (n ¼ mean of 4 experiments with 15–40 cells/experiment analyzed  SD; Student’s t test). (e)
Immunodetection of lysosomal marker LAMP1 (green), GST-SHH-N (red), and megalin (blue) in control and patient NPCs at day 7 of
differentiation. Cells were treated with 10 mg/ml GST-SHH-N for 2 hours and counterstained with DAPI (gray). Bar ¼ 10 mm. Higher
magnifications of overview pictures are given as insets (bars ¼ 4 mm). Increased colocalization of megalin with GST-SHH-N in LAMP1þ
lysosomal vesicles (white signals) was noted in patient as compared with control NPC lines. To optimize viewing of this image, please see the
online version of this article at www.kidney-international.org.
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Figure 7 | Inhibition of lysosomal proteases prevents the ligand-induced decay of megalinR3192Q. (a) Neural precursor cells (NPCs) at
differentiation day 5 were treated overnight with 10 mg/ml GST-SHH-N in the absence or presence of lysosomal protease inhibitors (þ lyso.
inhibitor; see Supplementary Methods for details). Subsequently, megalin levels in cell lysates were determined by Western blotting. Detection
of a-tubulin served as a loading control. (b) Quantification of megalin levels in control and R3192Q_1 NPCs by densitometric scanning of
replicate Western blots (exemplified in panel a). Levels are given relative to GST-SHH-N without lysosomal inhibitors (set to 100%  SD).
Treatment with lysosomal inhibitors significantly increased levels of megalinR3192Q as compared with nontreated cells (right panel). No effect of
lysosomal inhibition was seen on levels of the wild-type receptor in control NPCs (left panel) (n ¼ 4 independent experiments, 2–3 biological
replicates/experiment). Statistical significance was determined using Student’s t test. ****P < 0.0001.
c l i n i ca l i nves t iga t i on J Flemming et al.: Molecular cause of megalin deficiencysevere bilateral myopia (þ7 dioptres). His sister was diagnosed at age 9
by family screening. Her renal function was normal (estimated
glomerular filtration rate: 93 ml/min per 1.73 m2). Urine evaluation
showed similar findings to her brother, including high urinary protein/
creatinine ratio (2.26 mg/mg), abnormal urinary excretion of low-
molecular-weight proteins (urinary beta 2 microglobulin/creatinine
ratio: 1.31 mg/mg), and mild hypercalciuria (urinary calcium/creati-
nine ratio: 0.25 mg/mg). A small phosphate leak was also noticed
(serum phosphate: 3.4 mg/dl; TmP/GFR: 2.7 mg/dl) without evidence
of hyperparathyroidism (intact parathyroid hormone 31 pg/ml). No
other serum or urinary abnormalities were noticed. Renal ultrasound
showed normal sized kidneys (approximately 50th percentile) with
discrete cortical hyperechogenicity. Her physical examination showed
normal blood pressure and was significant for severe bilateral myopia
(þ9 dioptres), short stature (height SD: 2.13), and mild overweight
(body mass index: 26.7).
Analysis of human specimen and cell lines
The study of human specimens and cell lines was approved by the
Ethics Committee of Ospedale Pediatrico Bambino Gesù (approval
no.: 1235_OPBG_2016). All subjects gave written informed consent
before participating in this study. Generation of iPSCs was per-
formed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit.
Differentiation of iPSCs to NPCs or RPTECs was performed ac-
cording to published protocols13,16 and detailed in Supplementary
Methods. Differentiation into the 3 germ layers was carried out
using a commercial kit according to the supplier’s recommendations166(Trilineage Differentiation Kit, Miltenyi Biotec, Bergisch Gladbach,
Germany, No. 130-115-660). Immunodetection of megalin in renal
biopsies and documentation of urinary loss of receptor ligands in
spot urine of patients and control subjects shown here were per-
formed as reported earlier.11
Cell studies
Studies were conducted in NPCs or RPTECs using the experimental
conditions described in the respective figure legends. GST and GST-
SHH-N used as ligands were affinity purified from bacterial cultures
using glutathione affinity chromatography as described previously.4
Lysozyme purified from hen egg white was obtained commercially
(Abcam, Cambridge, UK, 10837059001). Experimental details for
immunodetection of proteins using Western blotting or immuno-
cytochemistry are given in the Supplementary Methods section.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from cell cultures using the RNeasy Mini
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions with an additional step of treating the RNA with RNase-
free DNase I for 15 minutes at room temperature. RNA (500 ng to 1
mg) was reverse transcribed using the High Capacity RNA to cDNA
Kit (Applied Biosystems, Foster City, CA). For cDNA amplification,
TaqMan-Oligonucleotide probes were used with the TaqMan Gene
Expression Master Mix (Applied Biosystems) on a 7900 HT Fast Real
time PCR System (Thermo Fisher Scientific, Waltham, MA) and the
Sequence detection system V2.4 (Thermo Fisher Scientific). ResultsKidney International (2020) 98, 159–167
J Flemming et al.: Molecular cause of megalin deficiency c l i n i ca l i nves t iga t ionwere analyzed using the comparative cycle threshold method
normalized to GAPDH.22
Statistical analysis
All statistical analysis was performed using the GraphPad Prism 7.0
software (San Diego, CA). The applied statistical tests are indicated
in the respective figure legend. Data are presented as mean  SD. To
determine the degree of colocalization between megalin and LAMP1
or GST-SHH-N, images with comparable background were taken for
analysis and background correction was performed. Images were
converted to 8-bit pixel images and individual cells were automati-
cally outlined to define a region of interest. ImageJ was used to assess
the Mander’s colocalization coefficient, indicating the fraction of
megalin colocalizing with LAMP1 or GST-SHH-N.23
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